肝硬化及肝细胞癌患者肠道微生态组成和结构的初步分析

周冷潇; 韩涛; 刘保文; 高英堂; 韩海燕

doi:10.3969/j.issn.1001-5256.2017.09.022

肝硬化及肝细胞癌患者肠道微生态组成和结构的初步分析

DOI: 10.3969/j.issn.1001-5256.2017.09.022

1. 天津医科大学三中心临床学院天津市第三中心医院肝内科天津市人工细胞重点实验室天津市肝胆疾病研究所
2. 天津市河东区口腔医院

基金项目:

国家科技重大专项(2016ZX10002008-07)；天津市科技计划项目(13RCGFSY19200)；

详细信息

中图分类号: R575.2;R735.7
计量
- 文章访问数: 2405
- HTML全文浏览量: 49
- PDF下载量: 549
- 被引次数: 0
出版历程
- 收稿日期: 2017-03-20
- 出版日期: 2017-09-20

A preliminary analysis of composition and structure of intestinal microbiota in patients with liver cirrhosis or hepatocellular carcinoma

The Third Central Clinical College of Tianjin Medical University

Research funding:

摘要

摘要: 目的比较分析肝硬化和肝硬化基础上发生肝细胞癌（HCC）的患者远端肠道菌群的差异,探讨肝硬化患者发生HCC与肠道菌群变化的关系。方法收集2015年12月-2016年5月天津市第三中心医院肝内科住院的慢性肝病患者35例,包括20例肝硬化患者（肝硬化组）和15例肝硬化合并HCC患者（HCC组）。收集患者粪便标本,提取其肠道细菌总DNA,采用Roche 454测序技术对16S r DNA V3-V6可变区测序,并进行生物信息分析（物种分类、丰度分析及多样性分析）。计量资料组间比较采用t检验,计数资料组间比较采用Mann-Whitney U检验。结果 20个肝硬化患者样品平均OTU为306.50±163.76,15个HCC患者样品平均OTU为357.24±168.85,2组患者OTU及alpha多样性指数相比,差异没有统计学意义（P值均>0.05）。粪便菌群序列包括的菌门主要有放线菌门（Actinobacteria）、拟杆菌门（Bacteroidetes）、厚壁菌门（Firmicutes）和变形菌门（Proteobacteria）。属种定量及组成分析发现,肝硬化组和HCC组患者肠道内多种细...
- 肝硬化 /
- 癌,肝细胞 /
- 肠杆菌科
Abstract: Objective To investigate the differences in intestinal microbiota between patients with liver cirrhosis and those with hepatocellular carcinoma ( HCC) complicated by liver cirrhosis, as well as the association between the change in intestinal microbiota and the development of HCC. Methods A total of 35 patients with chronic liver diseases who were hospitalized in Department of Hepatology in Tianjin Third Central Hospital from December 2015 to May 2016 were enrolled, among whom 20 patients had liver cirrhosis ( liver cirrhosis group) and 15 had HCC complicated by liver cirrhosis ( HCC group) . Fecal samples were collected from all patients, total bacterial DNA was extracted, and Roche 454 sequencing was used to determine the sequence of the V3-V6 viable regions of 16 S r DNA. A bioinformatics analysis was also performed ( species taxonomy, abundance analysis, and diversity analysis) . The t-test was used for comparison of continuous data between groups, and the Mann-Whitney U test was used for comparison of categorical data between groups. Results The mean number of operational taxonomic units ( OTUs) in the samples from the 20 liver cirrhosis patients was 306. 50 ±163. 76, and that in the samples from the 15 HCC patients was 357. 24± 168. 85; there were no significant differences in the number of OTUs and alpha diversity between the two groups of patients ( both P >0. 05) . The bacteria in fecal samples included Actinobacteria, Bacteroidetes, Firmicutes, and Proteobacteria. Genus-species and composition analyses showed that there was a significant difference in relative abundance of various bacteria in the intestine between the liver cirrhosis group and the HCC group, and compared with the HCC group, the liver cirrhosis group had significant increases in the proportions of Actinobacteria ( 0. 21% vs 0. 06%, U =89. 000, P =0. 043) , Bifidobacterium ( 0. 16% vs 0. 04%, U =90. 000, P =0. 046) , and Clostridium ( 0. 13% vs 0. 08%, U = 90. 000, P = 0. 046) and significant reductions in the proportions of Rikenellaceae ( 0. 58% vs 2. 30%, U = 82. 000, P = 0. 023) and Christenellaceae ( 0. 01% vs 0. 08%, U = 84. 500, P = 0. 028) . Conclusion There are significant differences in the composition of intestinal microbiota between patients with liver cirrhosis and those with HCC complicated by liver cirrhosis, while the specific mech anisms of the interaction between the differences and HCC with liver cirrhosis remained unclear.
- liver cirrhosis /
- carcinoma, hepatocellular /
- enterobacteriaceae

HTML全文

参考文献(32)

[1]YE SL.Current challenges to primary liver cancer research[J].J Clin Hepatol, 2015, 31 (6) :819-823. (in Chinese) 叶胜龙.原发性肝癌研究当前面临的挑战[J].临床肝胆病杂志, 2015, 31 (6) :819-823.

[2]QIN N, YANG F, LI A, et al.Alterations of the human gut microbiome in liver cirrhosis[J].Nature, 2014, 513 (7516) :59-64.

[3]CHEN Y, YANG F, LU H, et al.Characterization of fecal microbial communities in patients with liver cirrhosis[J].Hepatology, 2011, 54 (2) :562-572.

[4]LU H, WU Z, XU W, et al.Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection.Intestinal microbiota of HBV cirrhotic patients[J].Microb Ecol, 2011, 61 (3) :693-703.

[5]Ministry of Health of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2011) [J].J Clin Hepatol, 2011, 27 (11) :1141-1159. (in Chinese) 中华人民共和国卫生部.原发性肝癌诊疗规范 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1159.

[6]CAPORASO JG, KUCZYNSKI J, STOMBAUGH J, et al.QIIME allows analysis of high-throughput community sequencing data[J].Nat Methods, 2010, 7 (5) :335-336.

[7]Greengenes.The greengenes database downloads[DB/OL].http://greengenes.secondgenome.com/downloads/database/13_5.

[8]TAO X, WANG N, QIN W.Gut Microbiota and Hepatocellular Carcinoma[J].Gastrointest Tumors, 2015, 2 (1) :33-40.

[9]QIN J, LI R, RAES J, et al.A human gut microbial gene catalogue established by metagenomic sequencing[J].Nature, 2010, 464 (7285) :59-65.

[10]MADSEN BS, HAVELUND T, KRAG A.Targeting the gut-liver axis in cirrhosis:antibiotics and non-selective beta-blockers[J].Adv Ther, 2013, 30 (7) :659-670.

[11]SUNG JY, SHAFFER EA, COSTERTON JW.Antibacterial activity of bile salts against common biliary pathogens.Effects of hydrophobicity of the molecule and in the presence of phospholipids[J].Dig Dis Sci, 1993, 38 (11) :2104-2112.

[12]GUNNARSDOTTIR SA, SADIK R, SHEV S, et al.Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension[J].Am J Gastroenterol, 2003, 98 (6) :1362-1370.

[13]WIEST R, LAWSON M, GEUKING M.Pathological bacterial translocation in liver cirrhosis[J].J Hepatol, 2014, 60 (1) :197-209.

[14]LI DY, YANG M, EDWARDS S, et al.Nonalcoholic fatty liver disease:for better or worse, blame the gut microbiota?[J].JPEN J Parenter Enteral Nutr, 2013, 37 (6) :787-793.

[15]SEKI E, de MINICIS S, OSTERREICHER CH, et al.TLR4 enhances TGF-beta signaling and hepatic fibrosis[J].Nat Med, 2007, 13 (11) :1324-1332.

[16]LOO TM, KAMACHI F, WATANABE Y, et al.Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity[J].Cancer Discov, 2017, 7 (5) :522-538

[17]BRANDI G, de LORENZO S, CANDELA M, et al.Microbiota, NASH, HCC and the potential role of probiotics[J].Carcinogenesis, 2017, 38 (3) :231-240.

[18]HUANG XF.The role of bile acid signaling in liver carcinogenesis and liver regeneration[D].Fuzhou:Fujian Med Univ, 2007. (in Chinese) 黄雄飞.胆酸信号与肝癌发生和肝脏再生[D].福州:福建医科大学, 2007.

[19]YOSHIMOTO S, LOO TM, ATARASHI K, et al.Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome[J].Nature, 2013, 499 (7456) :97-101.

[20]YU LX, YAN HX, LIU Q, et al.Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents[J].Hepatology, 2010, 52 (4) :1322-1333.

[21]DAPITO DH, MENCIN A, GWAK GY, et al.Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4[J].Cancer Cell, 2012, 21 (4) :504-516.

[22]ZHANG HL, YU LX, YANG W, et al.Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats[J].J Hepatol, 2012, 57 (4) :803-812.

[23]MITSUOKA T.Bifidobacteria and their role in human health[J].J Ind Microbiol, 1990, 6 (4) :263-267.

[24]SHETH AA, GARCIA-TSAO G.Probiotics and liver disease[J].J Clin Gastroenterol, 2008, 42 (Suppl 2) :s80-s84.

[25]MALAGUARNERA M, GRECO F, BARONE G, et al.Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy:a randomized, double-blind, placebo-controlled study[J].Dig Dis Sci, 2007, 52 (11) :3259-3265.

[26]ZHANG M, ZHENG M, WU Z, et al.Alteration of gut microbial community after N, N-Dimethylformamide exposure[J].J Toxicol Sci, 2017, 42 (2) :241-250.

[27]HE J, LIU J, KONG Y, et al.Serum activities of liver enzymes in workers exposed to sub-TLV levels of dimethylformamide[J].Int J Occup Med Environ Health, 2015, 28 (2) :395-398.

[28]KIM KW, CHUNG YH.Hepatotoxicity in rats treated with dimethylformamide or toluene or both[J].Toxicol Res, 2013, 29 (3) :187-193.

[29]LIU HX, ROCHA CS, DANDEKAR S, et al.Functional analysis of the relationship between intestinal microbiota and the expression of hepatic genes and pathways during the course of liver regeneration[J].J Hepatol, 2016, 64 (3) :641-650.

[30]ISLAM KB, FUKIYA S, HAGIO M, et al.Bile acid is a host factor that regulates the composition of the cecal microbiota in rats[J].Gastroenterology, 2011, 141 (5) :1773-1781.

[31]RIDLON JM, ALVES JM, HYLEMON PB, et al.Cirrhosis, bile acids and gut microbiota:unraveling a complex relationship[J].Gut Microbes, 2013, 4 (5) :382-387.

[32]GRAT M, WRONKA KM, KRASNODEBSKI M, et al.Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis[J].Transplant Proc, 2016, 48 (5) :1687-1691.

施引文献

资源附件(0)

访问统计